Results: The relative amount of COX-2 mRNA and VEGF mRNA expressed in atrophic endometrium, complex endometrial hyperplasia and endometrial adenocarcinoma were 8.86±19.12, 55.76±48.46, 132.64±56.99, and 15.23±24.86, 57.30±49.40 and 142.31±59.45, respectively.
The c-myc gene expression in endometrial carcinoma,endometrial tissue surrounding the tumor and normal endometrium were determined by using c-myc DNA labelled with Biotin-11-DUTP and in-situ hybridization with the above tissues.
Results: In 55 cases of ultrasonographic type Ⅰand Ⅱ (thickness of endometrium<5mm) endonetrium shrinkage were confirmed by pathological examination. Of 23 cases of ultrasonography type Ⅲ and Ⅳ (thickness of endometrium>5mm), 2 cases were diagnosed as endometrium shrinkage, 10 cases as endometrium polyp, 5 cases as endometrium proliferation and 6 cases as endometrium adenocarcinoma.
Methods:Immunohistochemical staining S-P method was used to detect the expression of c-Met and CD147 in 20 cases of proliferative phase endometrium tissues,20 cases of secretory phase endometrium tissues,and 55 cases of endometrium adenocarcinoma tissues.
The patient developed two consecutive vaginal tumors diagnosed as metastases of the previously diagnosed endometrial carcinoma.
To assess survival, disease-specific survival, acute and late toxicity and quality of life in patients with curable endometrial carcinoma treated with adjuvant or primary radiotherapy at the age ≥ 75 years.
Expression and significance of Smad4 and p21WAF1 in endometrial carcinoma
Objective: To investigate the expression of Smad4 and p21WAF1 in endometrial carcinoma and its clinical significance.
Methods: Immunohistochemical method was used to detect Smad4 and p21WAF1 expression in 56 cases of endometrial carcinoma.